PC
SCLN

Passport Capital’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Passport Capital’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-13,513
Closed -$68K – 248
2013
Q4 		$68K Buy
+13,513
New +$65K ﹤0.01% 141

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
QBFM
QS Batterymarch Financial Management New York $3.78B AUM 22.02% 1-Year Est. Return

Passport Capital's SCLN Position: Q1 2014 in Review

Passport Capital sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2014, closing a stake of 13,513 shares — an estimated $68K sold.

Passport Capital first reported a position in SCLN in Q4 2013 and held it in 1 quarter. The position peaked at $68K in Q4 2013. 96 funds tracked by Wall St. Rank hold SCLN as of Q1 2014.

  • Passport Capital reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2014 after selling out during the quarter.
  • Passport Capital sold 13,513 Sciclone Pharmaceuticals Inc shares in Q1 2014, an estimated $68K.
  • Passport Capital first reported a position in Sciclone Pharmaceuticals Inc in Q4 2013 and held it in 1 quarter.
  • Passport Capital's Sciclone Pharmaceuticals Inc position peaked at $68K in Q4 2013.
  • 96 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2014.

Based on Passport Capital's 13F filing for Q1 2014, filed 15 May 2014.